

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7697044

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ASTELLAS PHARMA INC.	11/22/2022
RECEIVING PARTY DATA		
Name:	ASAHI PHARMA CO., LTD	
Street Address:	5-1, AZUMA 2-CHOME	
Internal Address:	TSUKUBA CITY	
City:	IBARAKI	
State/Country:	JAPAN	
Postal Code:	305-0031	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	RE49111
CORRESPONDENCE DATA		
Fax Number:	(203)327-6401	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2033274500	
Email:	amcofone@ogrp.com	
Correspondent Name:	OHLANDT, GREELEY, RUGGIERO AND PERLE, LLP	
Address Line 1:	ONE LANDMARK SQUARE	
Address Line 2:	10TH FLOOR	
Address Line 4:	STAMFORD, CONNECTICUT 06901	
ATTORNEY DOCKET NUMBER:	0015692REI/3238	
NAME OF SUBMITTER:	PAUL D. GREELEY	
SIGNATURE:	/Paul D. Greeley/	
DATE SIGNED:	12/15/2022	
Total Attachments: 2		
source=0015692REI_3238_Assignment#page1.tif		
source=0015692REI_3238_Assignment#page2.tif		

CORPORATE ASSIGNMENT

WHEREAS, ASTELLAS PHARMA INC., a corporation, with its principal place of business at 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (hereinafter referred to as "Assignor"), as owner of the invention fully described in U.S. Patent No. RE49111, issued on September 20, 2022, (hereinafter referred to as the Patent); and

WHEREAS, ASAHI PHARMA CO., LTD., a corporation, with its principal place of business at 5-1, Azuma 2-chome, Tsukuba City, Ibaraki 305-0031, Japan (hereinafter referred to as "Assignee"), and entitled wishes to acquire the entire right, title and interest in and to the invention, as well as to the Patent and all other corresponding foreign patent rights;

NOW THEREFORE, for valuable and legally sufficient considerations, receipt of which are hereby acknowledged, the Assignor sells, assigns and transfers to Assignee, its successors and assigns, the entire right, title and interest for the United States in and to the invention and the Patents and Patent Applications for the full term of any Letters Patent which issues therefrom;


The Assignor further agrees, for itself and its legal representatives, it will assist or direct the inventors to assist Assignee in the prosecution before the United States Patent Office and the Federal Courts of the Patent including renewals, continuations, continuation-in-parts, divisions, reissues and substitutions, that the Assignee elects to make covering the invention. The Assignor vests in Assignee like exclusive

title in and to all such other applications and Letters Patent. The Assignor will execute or direct the inventors to execute and deliver to Assignee any documents which may be requested by Assignee to carry out the terms of this Assignment; and

The Commissioner of Patents and Trademarks of the United States is authorized and requested to issue Letters Patent of the United States to Assignee. The Assignor also authorizes and requests the equivalent authorities in foreign countries to issue the patents of foreign countries to Assignee.

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized officer effective as of the 24th day of June, 2022.

ASTELLAS PHARMA INC

By: 
Name: Ken Kubota
Title: SVP, Business Development

Date: November 22, 2022


Witness Signature

Yuko Wako
Witness Printed Name

2-5-1, Nihonbashi-Honcho
Chuo-ku, Tokyo 103-8411, Japan
Witness Address